Akums Drugs and Pharmaceuticals Limited has announced the complete utilization of its Initial Public Offer (IPO) proceeds as of September 30, 2026. The final report from CRISIL Ratings Limited confirms that all funds raised have been deployed towards the intended objectives, including repayment of debt and general corporate purposes. This marks the end of the monitoring period for the IPO proceeds.
Final IPO Proceeds Utilization Report
Akums Drugs and Pharmaceuticals Limited has officially confirmed the full utilization of its Initial Public Offer (IPO) proceeds, with the final report submitted by CRISIL Ratings Limited, the designated Monitoring Agency. The report covers the quarter ended September 30, 2026, and signifies the completion of the fund deployment process as per the company’s stated objectives in its offer document.
Key Financial Closures
According to the final monitoring report, the company has successfully deployed the entire issue proceeds of Rs 6,800.00 million. The utilization primarily focused on the repayment/prepayment of indebtedness for the company and its subsidiaries, funding incremental working capital requirements, pursuing inorganic growth initiatives through acquisitions, and general corporate purposes (GCP). Notably, all net proceeds have been accounted for, with no unutilized funds remaining pending for deployment or reimbursement as of the quarter end.
End of Monitoring Period
With the complete utilization of the IPO proceeds, the requirement for submission of further reports from the Monitoring Agency has ceased, as per SEBI regulations. This final report from CRISIL Ratings Limited marks the conclusion of the monitoring of IPO fund utilization for Akums Drugs and Pharmaceuticals Limited.
Source: BSE
